Effect of matrine combined with cisplatin on the expression of XIAP in human rhabdomyosarcoma RD cells

Abstract

The combined effects of matrine (Mat) and cisplatin on the survival and apoptosis of rhabdomyosarcoma (RMS) RD cells, as well as the possible mechanism of the synergistic effect of Mat and cisplatin were investigated in the present study. RMS RD cells were divided and treated as follows: control group, 5 mg/l cisplatin group, Mat groups (0.5, 1.0 and 1.5 g/l), and Mat (0.5, 1.0 and 1.5 g/l) combined with 5 mg/l cisplatin groups. An MTT assay and flow cytometry were applied to detect the survival and apoptotic rates, respectively, while RT-PCR was applied to detect the expression levels of X-linked inhibitor of apoptosis protein (XIAP) mRNA in the RD cells of each group. The survival rates of RD cells in each experimental group were lower than in the control group, and the apoptotic rates were higher than those in the control group (P<0.05). An increase in drug concentrations led to the cell proliferation inhibitory and apoptotic rates of the single Mat groups increasing as a function of dose (pairwise comparison among the groups, P<0.05), while the proliferation inhibitory and apoptotic rates of Mat combined with the cisplatin groups under different concentration were significantly higher than those of the single Mat and single cisplatin groups under the same concentration (P<0.01). The expression levels of XIAP mRNA in the RD cells of each experimental group were lower than those in the control group (P<0.05). Additionally, the expression levels of XIAP mRNA in the group treated with Mat and cisplatin were significantly lower than those of the single cisplatin and single Mat groups (P<0.01). In conclusion, Mat and cisplatin are capable of inhibiting the proliferation of RD cells and inducing apoptosis by suppressing the XIAP mRNA expression levels.

A Systematic Review of the Pharmacology, Toxicology and Pharmacokinetics of Matrine

“…showed that MT combined with cisplatin, 5-fluorouracil, and paclitaxel, respectively, effectively inhibited the proliferation of A549 cells and showed dose-dependent anticancer effects ( Pu et al., 2018 ). It has been reported that a combination of MT and cisplatin synergistically inhibited proliferation, and induced apoptosis of rhabdomyosarcoma (RMS) RD cells, through a mechanism involving inhibition of mRNA expression of XIAP mRNA ( Li et al., 2016 ). Another study found that MT and cisplatin synergistically suppressed the growth of urothelial bladder cancer cells (EJ, T24, BIU and 5637 cells) by inhibiting the VEGF/PI3K/Akt signaling pathway ( Liao et al., 2017 ).…”

Matrine inhibits the metastatic properties of human cervical cancer cells via downregulating the p38 signaling pathway

“…Matrine exhibits a wide range of pharmacological effects and has long been applied to treat viral hepatitis (6), neuropathic pain (7), isoproterenol-induced cardiotoxicity inflammatory and other diseases (8,9). In addition, increasing evidence has revealed that matrine displays anticancer effects in various cancers, such as gastric (10), rhabdomyosarcoma (11), acute myeloid leukemia (12), osteosarcoma (13), prostate (14), breast (15) and lung cancer (16). Moreover, the antitumor mechanisms of matrine have been demonstrated to involve the blockade of cell cycle progression, the induction of apoptosis, the regulation of oncogene expression, the inhibition of cytokine production and the modulation of signaling pathways (17)(18)(19).…”

Matrine exerts antitumor activity in cervical cancer by protective autophagy via the Akt/mTOR pathway in vitro and in vivo

“…When Fa=0.5, isobologram analysis determined that the CI of the drugs in combination was <1.0, indicating that the two drugs had a synergistic effect. The effects of matrine and cisplatin have also been found to be synergistic in urothelial bladder cancer and rhabdomyosarcoma cells ( 21 , 39 ). Matrine may therefore increase the sensitivity of cervical cancer cells to cisplatin.…”